Search the Newsreel

Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD

Quantinno Capital Management LP significantly increased its stake in Revolution Medicines (RVMD) by 97.6% in the first quarter, now owning 63,360 shares valued at $6.16 million. Despite the company reporting a wider-than-expected quarterly loss of $3.06 per share, institutional investors hold 94.34% of the …

Evommune Inc. (EVMN) Advances 2.76% as Shares Test Key Resistance Near $14 - Aggressive Growth Picks

Gevo (GEVO) Earnings Date and Reports 2026

Evolent Health (NYSE:EVH) Reports Bullish Q2 CY2026, Stock Jumps 18.2%

Revolve Group (RVLV) Stock Faces Valuation Heat After Strong Q2 Growth

Evommune (EVMN) Earnings Date and Reports 2026

Evotec (EVO) Projected to Post Earnings on Thursday

Evotec SE (EVO) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Devon Energy (DVN) Stock Retreat Deepens As Synergy Doubts Persist

Gevo (NASDAQ:GEVO) Reports Upbeat Q2 CY2026, Stock Soars

Earnings call transcript: Evolus tops revenue forecast in Q2 2026, shares rise

Evolus, Inc. Q2 2026: Revenue $84.08M, EPS ($0.12) — 10-Q Summary

Evolus, Inc. reported its Q2 2026 financial results, with revenue increasing to $84.08 million from $69.39 million in the prior year quarter, marking a 21.2% year-over-year growth. The company also narrowed its net loss, reporting a diluted EPS of ($0.12) compared to ($0.27) a …

Evolus targets $450M-$500M revenue and 13%-15% adjusted EBITDA margin in 2028 while raising 2026 revenue outlook to $330M-$337M

Earnings Call Insights: Evolus (EOLS) Q2 2026 MANAGEMENT VIEW * "The second quarter represents a meaningful inflection point for Evolus." (President, CEO & Director David Moatazedi) * "We delivered 21% revenue growth, generated our third consecutive quarter of positive adjusted EBITDA, expanded our international …

Revolution Medicines (NASDAQ:RVMD) Announces Earnings Results

Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases

Evotec SE announced a strategic R&D collaboration with Odyssey Therapeutics, Inc. to discover new treatments for autoimmune and inflammatory diseases. The partnership will leverage Evotec's AI-enabled discovery platform and advanced screening capabilities with Odyssey's disease biology expertise to accelerate the identification of drug candidates. …

Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026

Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments and increased its 2026 spending forecast to $2.1 billion to $2.2 billion to advance late-stage oncology programs and prepare for a potential first product launch. The company's lead drug, daraxonrasib, cleared a …

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Evolus, Inc. (EOLS) reported break-even quarterly earnings per share for Q2 2026, surpassing the Zacks Consensus Estimate of a $0.01 loss and significantly improving from a $0.24 loss a year ago. The company also exceeded revenue expectations, posting $84.08 million against an estimated $82.02 …

Devon Energy Continues to Benefit From Its Delaware Basin Production and Its Multi-Asset Portfolio

Devon Energy has strategically transformed its portfolio through divestitures and mergers, including with WPX Energy and Corterra. These moves allowed the company to shed non-core or high-cost assets, recycle cash, and pivot towards the Delaware Basin while also gaining exposure in the Bakken and …

Devon Energy Corp (DVN) (Q2 2026) Earnings Call Highlights: Strong Results, Synergy Progress, ...

This article first appeared on GuruFocus. Release Date: August 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Delivered strong Q2 2026 results, beating guidance on oil production, total production, operating costs, and …

Revolution Medicines Q2 Net Loss Widens

Revolution Medicines reported a significant widening of its net loss in Q2, increasing to $111.4 million from $70.8 million year-over-year, largely due to increased research and development expenses. Despite the loss, the company exceeded revenue expectations with $9.3 million, up from $2.1 million in …

Evolus Q2 2026 slides: profitability streak continues, guidance raised

Evolus Inc. reported strong Q2 2026 results, with revenue up 21% year-over-year to $84.1 million, marking its third consecutive quarter of positive adjusted EBITDA. The company raised its full-year 2026 revenue guidance to $330-$337 million and reaffirmed its long-term target of $450-$500 million by …

Devon Holds Asset Plans Close as Coterra Synergies Take Shape

The article discusses how Devon Energy is keeping its asset plans under wraps as it works on integrating synergies with Coterra. It highlights Devon's strategic approach following the merger, focusing on the potential for collaboration and operational efficiencies.

Revolution Medicines falls on second quarter earnings miss

Revolution Medicines (NASDAQ:RVMD) reported a significant earnings miss for the second quarter, with a loss of -$3.06 per share against an estimated -$1.96. The net loss for the quarter reached $644.4 million, impacted by a non-cash charge related to an acquisition. Despite the financial …

Evolus (EOLS) Releases Q2 2026 Earnings: Revenue Growth and Narrower Losses

Evolus (EOLS) reported strong Q2 2026 earnings, with revenue reaching $84.1 million, a 21.2% increase year-over-year, and slightly exceeding analyst estimates. The company also improved its financial performance by narrowing its operating and net losses. Insider trading activity showed sales by executives, while institutional …

Evolus (Nasdaq: EOLS) posts higher sales and manages sizable debt load

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Revolution Medicines announced its Q2 2026 financial results and provided an update on corporate progress, highlighting the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and the rapid implementation of an Expanded Access Program. The company also reported encouraging new combination …

Evolus (NASDAQ: EOLS) lifts 2026 guidance after Q2 revenue hits $84.1 million

Evolus (NASDAQ: EOLS) reported strong Q2 2026 financial results with net revenue of $84.1 million, a 21% increase year-over-year, and positive adjusted EBITDA of $4.7 million. This marks the third consecutive quarter of positive adjusted EBITDA for the company. Consequently, Evolus has raised its …

Evogene Ltd. (EVGN) director boosts stake with 800,000-share buy

Evogene Ltd. director Leon Recanati significantly increased his direct ownership in the company by purchasing 800,000 Ordinary Shares on August 4, 2026, at a weighted average price of $0.50 per share. This transaction brings his total direct holdings to 883,886 Ordinary Shares. The insider …

Arizona Gold & Silver secures C$12M strategic investment from Evolution Mining

Arizona Gold & Silver Inc (TSX-V:AZS, OTCQB:AZASF, FRA:A9J0) CEO Mike Stark joined Steve Darling from Proactive to discuss a C$12 million strategic investment from Evolution Mining, which will acquire 15,056,004 units of the company through a non-brokered private placement at C$0.80 per unit. Stark …

Devon Q2 Earnings Surpass Estimates on Strong Oil Output and Pricing

Devon Energy Corporation DVN reported second-quarter 2026 adjusted earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.30 by 20.77%. GAAP earnings were $2.03 per share, up 44% from $1.41 a year ago. Total Revenues Revenues of $7.41 billion surpassed the consensus …

Earnings Call: Devon Energy übertrifft Prognosen für Q2 2026, Aktie gibt dennoch nach

Key Points Interested in Devon Energy Corporation? Here are five stocks we like better. Devon exceeded Q2 guidance, generating $1.7 billion in adjusted free cash flow while beating targets for oil production, total production, operating costs and capital spending. The company tightened its 2026 …

Informe de resultados: Devon Energy supera las estimaciones del 2T 2026, pero sus acciones caen

Compass, Revolve Group Seen With Upside Among Cloud-Based Platform Firms, Morgan Stanley Says

Compass (COMP) and Revolve Group (RVLV) have more upside compared with MNTN (MNTN) and Opendoor Tech PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Gevo (GEVO) Q2 Earnings Report Preview: What To Look For

Gevo (NASDAQ:GEVO), a renewable fuels producer, is set to report its Q2 earnings this Thursday. The company missed revenue expectations last quarter but met EPS estimates, with analysts anticipating a 2.8% year-on-year revenue growth for the upcoming report. Despite missing Wall Street's revenue estimates …

How Strong Q2 Results And Raised Output Guidance At Devon Energy (DVN) Have Changed Its Investment Story

Devon Energy (DVN) reported strong Q2 2026 results, exceeding production guidance with 1,359,000 Boe per day total production and 503,000 barrels per day oil output, along with revenues of US$7,417 million and net income of US$1,911 million. This performance, driven by Delaware Basin wells, …

Revolve Q2 Earnings Beat on Expanding Customer Base & Higher Margins

Revolve Group, Inc. RVLV delivered a strong second quarter of 2026, marked by broad-based sales growth, accelerating customer acquisition and improved profitability. Double-digit gains across both segments and geographies reflected accelerating customer demand, while a lower return rate and better markdown execution supported margins. …